Biomarin Pharmaceutical (BMRN) Cost of Revenue (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Cost of Revenue came in at $195.0 million in Q1 2026, up 28.66% YoY from $151.6 million in Q1 2025, and down 29.27% on a QoQ basis from $275.7 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Cost of Revenue (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Cost of Revenue data on file, last reported at $195.0 million in Q1 2026.
- Quarterly Cost of Revenue rose 28.66% year-over-year to $195.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $760.9 million (up 25.43% YoY) and the FY2025 annual result came in at $717.4 million, up 23.65% from the prior year.
- Cost of Revenue declined to $195.0 million in Q1 2026, from $275.7 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $275.7 million in Q4 2025 to a low of $116.3 million in Q3 2022.
- A 5-year average of $148.7 million and a median of $136.1 million in 2024 frame the typical range for Cost of Revenue.
- The widest YoY moves for Cost of Revenue: up 102.52% in 2025, down 25.67% in 2025.
- Tracing BMRN's Cost of Revenue over 5 years: stood at $146.6 million in 2022, then decreased by 5.94% to $137.9 million in 2023, then retreated by 1.3% to $136.1 million in 2024, then soared by 102.52% to $275.7 million in 2025, then slipped by 29.27% to $195.0 million in 2026.
- The last three Cost of Revenue figures came in at $195.0 million (Q1 2026), $275.7 million (Q4 2025), and $140.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 202.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 202.80 Mn |
| Jun 30, 2026 | 202.80 Mn |
| Mar 31, 2026 | 195.00 Mn |
| Mar 31, 2026 | 195.00 Mn |
| Dec 31, 2025 | 275.71 Mn |
| Dec 31, 2025 | 275.71 Mn |
| Sep 30, 2025 | 140.09 Mn |
| Sep 30, 2025 | 140.09 Mn |
| Jun 30, 2025 | 150.09 Mn |
| Jun 30, 2025 | 150.09 Mn |
| Mar 31, 2025 | 151.56 Mn |
| Mar 31, 2025 | 151.56 Mn |
| Dec 31, 2024 | 136.14 Mn |
| Dec 31, 2024 | 136.14 Mn |
| Sep 30, 2024 | 188.46 Mn |
| Sep 30, 2024 | 188.46 Mn |
| Jun 30, 2024 | 130.46 Mn |
| Jun 30, 2024 | 130.46 Mn |
| Mar 31, 2024 | 125.18 Mn |
| Mar 31, 2024 | 125.18 Mn |